ArticlePLOS digital health2025
The Neuropathy Tracker-A mobile health application for ambulatory and self-administred assessment of neuropathy.
Article in PLOS digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Protocol for the NEURO-BREAC-02 Trial: Evaluation of a Self-Assessment Tool for Mild Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors.Journal of clinical medicine · 2026Article
- Article
- Measuring reading time: Comparing logged and self-reported data in relation to reading skills.PloS one · 2026Article
- Identification of Chemotherapy-Induced Peripheral Neuropathy-A Self-Administered Scoring System Tested in Breast Cancer Survivors: Protocol of the NEURO-BREAC Trial.Journal of personalized medicine · 2025Article
- Smartphone-based patient self-assessment of neuropathy grade: a validation study of the neuropathy tracker alignment with clinical tests.BMJ neurology open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral neuropathy is a common neurological disease and is a common complication of diabetes or cancer treatment. Early detection and treatment are crucial for improving the treatment of e.g., diabetic foot ulcers. However, neuropathy detection and monitoring requires examination of the motor and sensory systems and needs to be carried out in a clinical setting by trained professionals, leading to waiting time and delayed treatment. This paper presents the Neuropathy Tracker which is a Mobile Health (mHealth) tool for ambulatory self-assessment of neuropathy, which can be done by the patient at home. The app was designed in an iterative user-centered design (UCD) process involving neurologists, patients, and healthy subjects, thereby ensuring a high degree of clinical validity and usability. The assessment methodology in the app applies state-of-the-art neuropathy assessment methods and the app embodies a user-friendly and systematic assessment flow that guides the patient through the self-assessment. The Neuropathy Tracker tool was subject to a small feasibility study (N = 17), which showed a statistically significant (Pearson correlation ρ = 0.86, p < 0.05) but moderate (Concordance Correlation Coefficient (ρc) = 0.69) concurrent validity when compared with a standard clinical assessment method. All patients were able to complete the self-assessment without any help. As such, the technical and user experience design of the Neuropathy Tracker presents a stable mHealth tool that may be feasible for ambulatory self-assessment of neuropathy. Further clinical validation studies are, however, warranted before it is used in the clinical treatment of neuropathy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.